Baxter International Inc. · NYSE:BAX
Baxter International — 44th Annual J.P. Morgan Healthcare Conference (January 2026)
13 slides from Baxter International's conference presentation, Jan 12, 2026
Slide 1: 44th Annual J.P. Morgan Healthcare Conference
44th Annual J.P. Morgan Healthcare Conference Andrew Hider President & Chief Executive Officer January 12, 2026 1
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation includes forward-looking statements concerning the company's financial results (including the company’s net leverage target and estimated timing considerations) and operational, business development and regulatory activities. These forward-looking statements a
Slide 3: An Essential Global Partner Serving Critical Healthcare Needs
An Essential Global Partner Serving Critical Healthcare Needs Trusted global brand with market share leadership across core categories 350M+ 100+ patients treated countries supporting with products and care delivery solutions annually 38,000 40+ employees manufacturing sites worldwide Note: Facts an
Slide 4: Baxter at a Glance
Baxter at a Glance LTM Q3 2025 Sales by Segment1 LTM Q3 2025 Global Revenue (Continuing Operations)2 Medical Products & Therapies $5.2B Healthcare $11.0B Systems & Technologies $3.0B Pharmaceuticals $2.5B United States 55% International 45% 1Sales and related figures represent last twelve months (LT
Slide 5: Baxter's Diversified Portfolio of Essential Therapies & Solutions
Baxter’s Diversified Portfolio of Essential Therapies & Solutions Current Portfolio1 Hemostats Microsurgery Medical Hemodynamic & Sealants Infusion Systems Products & IV Therapies Monitoring Therapies 2CB & 3CB2 Clinical Nutrition ExactaMix Pro Adhesion Prevention Tissue & Bone Repair Infusion Thera
Slide 6: Well-Positioned Portfolio for an Evolving Global Healthcare Market
Well-Positioned Portfolio for an Evolving Global Healthcare Market Chronic Illness & Age Advancing Technology Care Across Settings Rising burden of chronic Acceleration of digital, AI- Shift toward and age-related enabled and connected- care decentralization and conditions across rapidly care ecosys
Slide 7: Baxter's Next Chapter: Pillars for Enterprise Evolution
Baxter’s Next Chapter: Pillars for Enterprise Evolution STABILIZE STRENGTHEN DRIVE The Business The Balance Sheet Continuous Improvement Focused on addressing Reducing leverage and Deploying Baxter GPS to areas impacting growth improving cash generation embed operational excellence and execution to
Slide 8: Growth & Performance System
GROWTH & PERFORMANCE SYSTEM 8
Slide 9: Growth & Performance System
GROWTH & PERFORMANCE SYSTEM 9
Slide 10: Advancing Innovation Across Our Portfolio
Advancing Innovation Across Our Portfolio Smart & Welch Allyn IQX Infusion Expansible Acute Connex 360 Platform Care Stretcher Q3/Q4 2025 Q4 2025+ Q1/Q2 20261 1Targeted product release date. 10
Slide 11: Disciplined Capital Allocation Driving Long-Term Shareholder Value
Disciplined Capital Allocation Driving Long-Term Shareholder Value CURRENT FUTURE Debt Invest For M&A 1 Repayment Growth • Strategic tuck-in opportunities that enhance growth capabilities • Near-term priority to strengthen • Continued organic investment in balance sheet to enhance core platforms – 1
Slide 12: Baxter Investment Thesis
Baxter Investment Thesis Essential products in market leading positions Focused on improving growth, margins and cash generation Advancing innovation across portfolio Enhanced capital allocation discipline; near-term focus on deleveraging to enhance financial flexibility Attractive valuation relativ
Slide 13: 44th Annual J.P. Morgan Healthcare Conference
44th Annual J.P. Morgan Healthcare Conference Andrew Hider President & Chief Executive Officer January 12, 2026 13
Baxter International — 44th Annual J.P. Morgan Healthcare Conference (January 2026) on 6ix